A Phase 3 interventional study of Benralizumab and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 342 sites in 30 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 49th largest by enrollment of the 194 interventional ones that give a count, is one of 6 that started in 2019, is one of 76 in phase 3, and was the 225th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
AstraZeneca · Sites in France
Ages 18–99
AstraZeneca · Sites in India
Ages 18+
AstraZeneca · Sites in Argentina, Egypt, Mexico and 4 more countries
Ages 18+
AstraZeneca · Sites in Argentina, Colombia, Egypt and 9 more countries
Ages 30–80
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
284 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 57 · Phase 3 77 · Phase 4 19
First in 1999; this study’s year is marked. 6 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 689 is above the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 137 across the 194 interventional studies, 976 across the 89 observational. Of the 264 that completed or were terminated, 128 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 179 (49%) have results posted.
9 of the studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06712563AstraZenecaPooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting | 2026-12-14 |
| NCT07245576AstraZenecaAssess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis | 2027-04-30 |
| NCT07315958AstraZenecaStudy for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics | 2027-04-30 |
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
| NCT07307781AstraZenecaStudy of Patient With Frequent Exacerbations in Moscow | 2027-06-25 |
Add all 9 to your calendar (.ics) → With an account.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 3 study to evaluate the efficacy and safety of a benralizumab in patients with moderate to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils (≥300/μL).
Eligible patients must have a history of ≥2 moderate and/or severe COPD exacerbations in the previous year despite receiving triple (ICS/LABA/LAMA) background therapy for at least 3 months and ICS-based dual inhaled treatment for the remainder of the year. Eligible patients must also have an elevated blood eosinophil count.
The treatment period will be of variable duration and will continue until the last patient has the opportunity to complete a minimum of 56 weeks, at which point all patients will complete the study. The primary endpoint will be analyzed at Week 56.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Documented history of 2 or more COPD exacerbations that required treatment with systemic and/or hospitalization within 52 weeks prior to enrollment.
Documented use of triple (ICS/LABA/LAMA) background therapy for COPD for ≥3 months immediately prior to enrollment.
Women not of childbearing potential are defined as women who are either permanently sterilized or (confirmed by FSH test for women \<50 years).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administrated subcutaneously (SC) every 4 weeks for the first 3 doses, then every 8 weeks
Biological: Benralizumab
Administrated subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks
Biological: Placebo
Benralizumab solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.
Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.
Annualized Rate of Moderate or Severe COPD Exacerbations of Participants With >=3 Exacerbations in the Previous Year.
Moderate or severe COPD exacerbation is defined by symptomatic worsening of COPD requiring: Use of systemic corticosteroids for at least 3 days; and/or Use of antibiotics; and/or An inpatient hospitalization or death due to COPD. Exacerbations per participant-year = 365.25\*Total Number of Exacerbations / Total time at risk within the treatment group (days)
Time frame: up to Week 56
Annualized Rate of Moderate or Severe COPD Exacerbations of Participants With >=2 Exacerbations in the Previous Year
Moderate or severe COPD exacerbation is defined by symptomatic worsening of COPD requiring: Use of systemic corticosteroids for at least 3 days; and/or Use of antibiotics; and/or An inpatient hospitalization or death due to COPD. Exacerbations per participant-year = 365.25\*Total Number of Exacerbations / Total time at risk within the treatment group (days)
Time frame: up to Week 56
Key Secondary Endpoint: Annualized Rate of Severe COPD Exacerbations of Participants With >=3 Exacerbations in the Previous Year
Severe COPD exacerbation is defined by symptomatic worsening of COPD requiring an inpatient hospitalization or results in death due to COPD. Exacerbations per participant-year = 365.25\*Total Number of Exacerbations / Total time at risk within the treatment group (days)
Time frame: Through study completion, a maximum of 296 weeks
Key Secondary Endpoint: Annualized Rate of Severe COPD Exacerbations of Participants With >=2 Exacerbations in the Previous Year
Severe COPD exacerbation is defined by symptomatic worsening of COPD requiring an inpatient hospitalization or results in death due to COPD. Exacerbations per participant-year = 365.25\*Total Number of Exacerbations / Total time at risk within the treatment group (days)
Time frame: Through study completion, a maximum of 296 weeks
Key Secondary Endpoint: Change From Baseline in SGRQ Total and Domain Scores at Week 56 of Participants With >=3 Exacerbations in the Previous Year
The St. George's Respiratory Questionnaire (SGRQ) is a 50-item PRO instrument developed to measure the health status of patients with airway obstruction diseases. The questionnaire is divided into 2 parts: part 1 consists of 8 items pertaining to the severity of respiratory symptoms in the preceding 4 weeks; and part 2 consists of 42 items related to the daily activity and psychosocial impacts of the individual's respiratory condition. The SGRQ yields a total score and 3 domain scores (symptoms, activity, and impacts). The total score indicates the impact of disease on overall health status. This total score is expressed as a percentage of overall impairment, in which 100 represents the worst possible health status and 0 indicates the best possible health status. Likewise, the domain scores range from 0 to 100, with higher scores indicative of greater impairment.
Time frame: up to Week 56
Key Secondary Endpoint: Change From Baseline in SGRQ Total and Domain Scores at Week 56 of Participants With >=2 Exacerbations in the Previous Year
The St. George's Respiratory Questionnaire (SGRQ) is a 50-item PRO instrument developed to measure the health status of patients with airway obstruction diseases. The questionnaire is divided into 2 parts: part 1 consists of 8 items pertaining to the severity of respiratory symptoms in the preceding 4 weeks; and part 2 consists of 42 items related to the daily activity and psychosocial impacts of the individual's respiratory condition. The SGRQ yields a total score and 3 domain scores (symptoms, activity, and impacts). The total score indicates the impact of disease on overall health status. This total score is expressed as a percentage of overall impairment, in which 100 represents the worst possible health status and 0 indicates the best possible health status. Likewise, the domain scores range from 0 to 100, with higher scores indicative of greater impairment.
Time frame: up to Week 56
Key Secondary Endpoint: Change From Baseline in Pre-bronchodilator FEV1 (mL) at Week 56 of Participants With >=3 Exacerbations in the Previous Year
Pre-bronchodilator forced expiratory volume in 1 second (FEV1) is defined as the volume of air exhaled from the lungs in the first second of forced expiration.
Time frame: up to Week 56
Key Secondary Endpoint: Change From Baseline in Pre-bronchodilator FEV1 (mL) at Week 56 of Participants With >=2 Exacerbations in the Previous Year
Pre-bronchodilator forced expiratory volume in 1 second (FEV1) is defined as the volume of air exhaled from the lungs in the first second of forced expiration.
Time frame: up to Week 56
Annualized Rate of COPD Exacerbations That Are Associated With an Emergency Room/Emergency Department Visit or a Hospitalization Due to COPD of Participants With >=3 Exacerbations in the Previous Year
The annualized rate of COPD exacerbations that are associated with an emergency room/emergency department (ER) or a hospitalization due to COPD through EOT are calculated similarly to the primary efficacy endpoint. The emergence room/emergence department (ER) and hospitalization due to COPD exacerbation are collected in COPDEX eCRF. Exacerbations per participant-year = 365.25\*Total Number of Exacerbations / Total time at risk within the treatment group (days)
Time frame: Through study completion, a maximum of 296 weeks
Annualized Rate of COPD Exacerbations That Are Associated With an Emergency Room/Emergency Department Visit or a Hospitalization Due to COPD of Participants With >=2 Exacerbations in the Previous Year
The annualized rate of COPD exacerbations that are associated with an emergency room/emergency department (ER) or a hospitalization due to COPD through EOT are calculated similarly to the primary efficacy endpoint. The emergence room/emergence department (ER) and hospitalization due to COPD exacerbation are collected in COPDEX eCRF. Exacerbations per participant-year = 365.25\*Total Number of Exacerbations / Total time at risk within the treatment group (days)
Time frame: Through study completion, a maximum of 296 weeks
Time From Randomization to the First Moderate or Severe COPD Exacerbation up to Week 56 of Participants With >=3 Exacerbations in the Previous Year
Time from randomization to the first moderate or severe COPD exacerbation = Start Date of first COPD exacerbation - Date of Randomization + 1. The time to first moderate or severe COPD exacerbation for patients who did experience a moderate or severe COPD exacerbation up to Week 56 were censored at Week 56, and for patients who discontinue or are lost-to-follow-up prior to Week 56, at the last time point after which an exacerbation could not be assessed.
Time frame: up to Week 56
Time From Randomization to the First Moderate or Severe COPD Exacerbation up to Week 56 of Participants With >=2 Exacerbations in the Previous Year
Time from randomization to the first moderate or severe COPD exacerbation = Start Date of first COPD exacerbation - Date of Randomization + 1. The time to first moderate or severe COPD exacerbation for patients who did experience a moderate or severe COPD exacerbation up to Week 56 were censored at Week 56, and for patients who discontinue or are lost-to-follow-up prior to Week 56, at the last time point after which an exacerbation could not be assessed.
Time frame: up to Week 56
Time From Randomization to the First Severe COPD Exacerbation of Participants With >=3 Exacerbations in the Previous Year
Time from randomization to the first severe COPD exacerbation = Start Date of first COPD exacerbation - Date of Randomization + 1. The time to first severe COPD exacerbation for patients who did experience a severe COPD exacerbation through EOT were censored at EOT, and for patients who discontinue or are lost-to-follow-up prior to EOT, at the last time point after which an exacerbation could not be assessed.
Time frame: From date of randomization until the date of first severe COPD exacerbation, assessed through study completion with a maximum of 296 weeks.
Time From Randomization to the First Severe COPD Exacerbation of Participants With >=2 Exacerbations in the Previous Year
Time from randomization to the first severe COPD exacerbation = Start Date of first COPD exacerbation - Date of Randomization + 1. The time to first severe COPD exacerbation for patients who did experience a severe COPD exacerbation through EOT were censored at EOT, and for patients who discontinue or are lost-to-follow-up prior to EOT, at the last time point after which an exacerbation could not be assessed.
Time frame: From date of randomization until the date of first severe COPD exacerbation, assessed through study completion with a maximum of 296 weeks.
Change From Baseline in COPD Assessment Tool (CAT) Total Score up to Week 56 of Participants With >=3 Exacerbations in the Previous Year.
The CAT is an 8-item PRO developed to measure the impact of COPD on health status. The instrument uses semantic differential 6-point response scales, which are defined by contrasting objectives to capture the impact of COPD. Content includes items related to cough, phlegm, chest tightness, breathlessness going up hills/stairs, activity limitation at home, confidence leaving home, sleep, and energy. The CAT total score is the sum of all item responses. Scores range from 0 to 40 with higher scores indicative of greater COPD impact on health status. A score cannot be calculated if \>2 responses are missing; when one or two items are missing, their scores can be set to the average of the non-missing item scores.
Time frame: up to Week 56
Change From Baseline in COPD Assessment Tool (CAT) Total Score up to Week 56 of Participants With >=2 Exacerbations in the Previous Year.
The CAT is an 8-item PRO developed to measure the impact of COPD on health status. The instrument uses semantic differential 6-point response scales, which are defined by contrasting objectives to capture the impact of COPD. Content includes items related to cough, phlegm, chest tightness, breathlessness going up hills/stairs, activity limitation at home, confidence leaving home, sleep, and energy. The CAT total score is the sum of all item responses. Scores range from 0 to 40 with higher scores indicative of greater COPD impact on health status. A score cannot be calculated if \>2 responses are missing; when one or two items are missing, their scores can be set to the average of the non-missing item scores.
Time frame: up to Week 56
Change From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS: COPD) Total and Domain Scores at Week 56 of Participants With >=3 Exacerbations in the Previous Year.
The E-RS: COPD is an 11-item PRO developed to evaluate the severity of respiratory symptoms of COPD. The E-RS: COPD is a subset of items from the EXACT-PRO. The E-RS: COPD was designed to be captured as part of the daily EXACT-PRO assessment. Summation of E-RS: COPD item responses produces a total score ranging from 0 to 40, with higher scores indicating greater severity. In addition to the total score, symptom domain scores can be calculated for breathlessness (5 items; score range: 0-17), cough and sputum (3 items; score range: 0-11) and chest symptoms (3 items; score range: 0-12) by summing the responses of items within a respective domain. As with the total score, higher domain scores indicate greater severity.
Time frame: up to Week 56
Change From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS: COPD) Total and Domain Scores at Week 56 of Participants With >=2 Exacerbations in the Previous Year.
The E-RS: COPD is an 11-item PRO developed to evaluate the severity of respiratory symptoms of COPD. The E-RS: COPD is a subset of items from the EXACT-PRO. The E-RS: COPD was designed to be captured as part of the daily EXACT-PRO assessment. Summation of E-RS: COPD item responses produces a total score ranging from 0 to 40, with higher scores indicating greater severity. In addition to the total score, symptom domain scores can be calculated for breathlessness (5 items; score range: 0-17), cough and sputum (3 items; score range: 0-11) and chest symptoms (3 items; score range: 0-12) by summing the responses of items within a respective domain. As with the total score, higher domain scores indicate greater severity.
Time frame: up to Week 56
All-cause and Respiratory-related Mortality of Participants With >=3 Exacerbations in the Previous Year.
Respiratory related causes of death are summarised based on the SOC = Respiratory, thoracic and mediastinal disorders. Death per 100 participant-year is compared between treatment groups. Death per 100 participant-year is defined as number of subjects with death divided by the total number of days at risk for death across all subjects in given treatment group, multiplied by 365.25 and then multiplied by 100. Total number of days at risk for death is defined as the duration from the first dose of IP to the date of death, or the duration from the first dose of IP to last visit for subjects without death.
Time frame: Through study completion, a maximum of 296 weeks.
All-cause and Respiratory-related Mortality of Participants With >=2 Exacerbations in the Previous Year.
Respiratory related causes of death are summarised based on the SOC = Respiratory, thoracic and mediastinal disorders. Death per 100 participant-year is compared between treatment groups. Death per 100 participant-year is defined as number of subjects with a death divided by the total number of days at risk for death across all subjects in given treatment group, multiplied by 365.25 and then multiplied by 100. Total number of days at risk for death is defined as the duration from the first dose of IP to the date of death, or the duration from the first dose of IP to last visit for subjects without death.
Time frame: Through study completion, a maximum of 296 weeks.
A total of 689 participants were randomized, 13 of which were removed from analyses due to GCP non-compliance before study unblinding. The remaining 676 participants were randomized to either the benralizumab 100 mg arm (331 participants) or placebo arm (345 participants) of the double-blind treatment period.
| Milestone | Benralizumab 100 mg | Placebo |
|---|---|---|
| Started | 331 | 345 |
| Completed | 289 | 306 |
| Not completed | 42 | 39 |
| Withdrew: Withdrawal by subject | 21 | 19 |
| Withdrew: Physician decision | 3 | 2 |
| Withdrew: Adverse event | 3 | 5 |
| Withdrew: Death | 13 | 8 |
| Withdrew: Other reasons | 2 | 5 |
| Milestone | Benralizumab 100 mg | Placebo |
|---|---|---|
| Started | 331 | 345 |
| Completed | 226 | 218 |
| Not completed | 105 | 127 |
| Withdrew: Withdrawal by subject | 58 | 65 |
| Withdrew: Physician decision | 5 | 4 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Adverse event | 4 | 10 |
| Withdrew: Death | 28 | 33 |
| Withdrew: Other reasons | 9 | 14 |
Moderate or severe COPD exacerbation is defined by symptomatic worsening of COPD requiring: Use of systemic corticosteroids for at least 3 days; and/or Use of antibiotics; and/or An inpatient hospitalization or death due to COPD. Exacerbations per participant-year = 365.25\*Total Number of Exacerbations / Total time at risk within the treatment group (days)
| Exacerbations per participant-year | Benralizumab 100 mg | Placebo |
|---|---|---|
| Annualized Rate of Moderate or Severe COPD Exacerbations of Participants With >=3 Exacerbations in the Previous Year. | 2.04 (1.69 to 2.46) | 2.46 (2.05 to 2.95) |
Moderate or severe COPD exacerbation is defined by symptomatic worsening of COPD requiring: Use of systemic corticosteroids for at least 3 days; and/or Use of antibiotics; and/or An inpatient hospitalization or death due to COPD. Exacerbations per participant-year = 365.25\*Total Number of Exacerbations / Total time at risk within the treatment group (days)
| Exacerbations per participant-year | Benralizumab 100 mg | Placebo |
|---|---|---|
| Annualized Rate of Moderate or Severe COPD Exacerbations of Participants With >=2 Exacerbations in the Previous Year | 1.86 (1.58 to 2.20) | 2.05 (1.75 to 2.41) |
Severe COPD exacerbation is defined by symptomatic worsening of COPD requiring an inpatient hospitalization or results in death due to COPD. Exacerbations per participant-year = 365.25\*Total Number of Exacerbations / Total time at risk within the treatment group (days)
| Exacerbations per participant-year | Benralizumab 100 mg | Placebo |
|---|---|---|
| Key Secondary Endpoint: Annualized Rate of Severe COPD Exacerbations of Participants With >=3 Exacerbations in the Previous Year | 0.37 (0.28 to 0.49) | 0.39 (0.30 to 0.52) |
Severe COPD exacerbation is defined by symptomatic worsening of COPD requiring an inpatient hospitalization or results in death due to COPD. Exacerbations per participant-year = 365.25\*Total Number of Exacerbations / Total time at risk within the treatment group (days)
| Exacerbations per participant-year | Benralizumab 100 mg | Placebo |
|---|---|---|
| Key Secondary Endpoint: Annualized Rate of Severe COPD Exacerbations of Participants With >=2 Exacerbations in the Previous Year | 0.37 (0.30 to 0.47) | 0.33 (0.26 to 0.42) |
The St. George's Respiratory Questionnaire (SGRQ) is a 50-item PRO instrument developed to measure the health status of patients with airway obstruction diseases. The questionnaire is divided into 2 parts: part 1 consists of 8 items pertaining to the severity of respiratory symptoms in the preceding 4 weeks; and part 2 consists of 42 items related to the daily activity and psychosocial impacts of the individual's respiratory condition. The SGRQ yields a total score and 3 domain scores (symptoms, activity, and impacts). The total score indicates the impact of disease on overall health status. This total score is expressed as a percentage of overall impairment, in which 100 represents the worst possible health status and 0 indicates the best possible health status. Likewise, the domain scores range from 0 to 100, with higher scores indicative of greater impairment.
| Score | Benralizumab 100 mg | Placebo |
|---|---|---|
| Total Score | -7.06 ± 16.804 | -4.95 ± 16.915 |
| Symptoms | -7.16 ± 18.495 | -5.46 ± 16.822 |
| Activity | -8.34 ± 19.958 | -6.81 ± 18.663 |
| Impacts | -6.37 ± 20.335 | -3.75 ± 21.387 |
The St. George's Respiratory Questionnaire (SGRQ) is a 50-item PRO instrument developed to measure the health status of patients with airway obstruction diseases. The questionnaire is divided into 2 parts: part 1 consists of 8 items pertaining to the severity of respiratory symptoms in the preceding 4 weeks; and part 2 consists of 42 items related to the daily activity and psychosocial impacts of the individual's respiratory condition. The SGRQ yields a total score and 3 domain scores (symptoms, activity, and impacts). The total score indicates the impact of disease on overall health status. This total score is expressed as a percentage of overall impairment, in which 100 represents the worst possible health status and 0 indicates the best possible health status. Likewise, the domain scores range from 0 to 100, with higher scores indicative of greater impairment.
| Score | Benralizumab 100 mg | Placebo |
|---|---|---|
| Total Score | -5.80 ± 16.185 | -3.89 ± 16.141 |
| Symptoms | -6.10 ± 18.104 | -4.97 ± 16.768 |
| Activity | -6.81 ± 19.381 | -4.96 ± 17.618 |
| Impacts | -5.20 ± 19.685 | -2.95 ± 20.592 |
Pre-bronchodilator forced expiratory volume in 1 second (FEV1) is defined as the volume of air exhaled from the lungs in the first second of forced expiration.
| mL | Benralizumab 100 mg | Placebo |
|---|---|---|
| Key Secondary Endpoint: Change From Baseline in Pre-bronchodilator FEV1 (mL) at Week 56 of Participants With >=3 Exacerbations in the Previous Year | 10.8 ± 268.48 | 17.3 ± 285.39 |
Pre-bronchodilator forced expiratory volume in 1 second (FEV1) is defined as the volume of air exhaled from the lungs in the first second of forced expiration.
| mL | Benralizumab 100 mg | Placebo |
|---|---|---|
| Key Secondary Endpoint: Change From Baseline in Pre-bronchodilator FEV1 (mL) at Week 56 of Participants With >=2 Exacerbations in the Previous Year | 18.3 ± 252.20 | 3.8 ± 259.60 |
The annualized rate of COPD exacerbations that are associated with an emergency room/emergency department (ER) or a hospitalization due to COPD through EOT are calculated similarly to the primary efficacy endpoint. The emergence room/emergence department (ER) and hospitalization due to COPD exacerbation are collected in COPDEX eCRF. Exacerbations per participant-year = 365.25\*Total Number of Exacerbations / Total time at risk within the treatment group (days)
| Exacerbations per participant-year | Benralizumab 100 mg | Placebo |
|---|---|---|
| Annualized Rate of COPD Exacerbations That Are Associated With an Emergency Room/Emergency Department Visit or a Hospitalization Due to COPD of Participants With >=3 Exacerbations in the Previous Year | 0.50 (0.39 to 0.64) | 0.60 (0.47 to 0.76) |
The annualized rate of COPD exacerbations that are associated with an emergency room/emergency department (ER) or a hospitalization due to COPD through EOT are calculated similarly to the primary efficacy endpoint. The emergence room/emergence department (ER) and hospitalization due to COPD exacerbation are collected in COPDEX eCRF. Exacerbations per participant-year = 365.25\*Total Number of Exacerbations / Total time at risk within the treatment group (days)
| Exacerbations per participant-year | Benralizumab 100 mg | Placebo |
|---|---|---|
| Annualized Rate of COPD Exacerbations That Are Associated With an Emergency Room/Emergency Department Visit or a Hospitalization Due to COPD of Participants With >=2 Exacerbations in the Previous Year | 0.48 (0.39 to 0.59) | 0.50 (0.41 to 0.61) |
Time from randomization to the first moderate or severe COPD exacerbation = Start Date of first COPD exacerbation - Date of Randomization + 1. The time to first moderate or severe COPD exacerbation for patients who did experience a moderate or severe COPD exacerbation up to Week 56 were censored at Week 56, and for patients who discontinue or are lost-to-follow-up prior to Week 56, at the last time point after which an exacerbation could not be assessed.
| Weeks | Benralizumab 100 mg | Placebo |
|---|---|---|
| Time From Randomization to the First Moderate or Severe COPD Exacerbation up to Week 56 of Participants With >=3 Exacerbations in the Previous Year | 31.7 (24.1 to 40.4) | 26.1 (21.1 to 31.1) |
Time from randomization to the first moderate or severe COPD exacerbation = Start Date of first COPD exacerbation - Date of Randomization + 1. The time to first moderate or severe COPD exacerbation for patients who did experience a moderate or severe COPD exacerbation up to Week 56 were censored at Week 56, and for patients who discontinue or are lost-to-follow-up prior to Week 56, at the last time point after which an exacerbation could not be assessed.
| Weeks | Benralizumab 100 mg | Placebo |
|---|---|---|
| Time From Randomization to the First Moderate or Severe COPD Exacerbation up to Week 56 of Participants With >=2 Exacerbations in the Previous Year | 33.0 (26.6 to 44.1) | 29.1 (25.6 to 33.0) |
Time from randomization to the first severe COPD exacerbation = Start Date of first COPD exacerbation - Date of Randomization + 1. The time to first severe COPD exacerbation for patients who did experience a severe COPD exacerbation through EOT were censored at EOT, and for patients who discontinue or are lost-to-follow-up prior to EOT, at the last time point after which an exacerbation could not be assessed.
| Weeks | Benralizumab 100 mg | Placebo |
|---|---|---|
| Time From Randomization to the First Severe COPD Exacerbation of Participants With >=3 Exacerbations in the Previous Year | 255.0 (157.1 to NA) | 194.6 (124.1 to NA) |
Time from randomization to the first severe COPD exacerbation = Start Date of first COPD exacerbation - Date of Randomization + 1. The time to first severe COPD exacerbation for patients who did experience a severe COPD exacerbation through EOT were censored at EOT, and for patients who discontinue or are lost-to-follow-up prior to EOT, at the last time point after which an exacerbation could not be assessed.
| Weeks | Benralizumab 100 mg | Placebo |
|---|---|---|
| Time From Randomization to the First Severe COPD Exacerbation of Participants With >=2 Exacerbations in the Previous Year | 255.0 (190.0 to NA) | NA (NA to NA) |
The CAT is an 8-item PRO developed to measure the impact of COPD on health status. The instrument uses semantic differential 6-point response scales, which are defined by contrasting objectives to capture the impact of COPD. Content includes items related to cough, phlegm, chest tightness, breathlessness going up hills/stairs, activity limitation at home, confidence leaving home, sleep, and energy. The CAT total score is the sum of all item responses. Scores range from 0 to 40 with higher scores indicative of greater COPD impact on health status. A score cannot be calculated if \>2 responses are missing; when one or two items are missing, their scores can be set to the average of the non-missing item scores.
| Score | Benralizumab 100 mg | Placebo |
|---|---|---|
| Change From Baseline in COPD Assessment Tool (CAT) Total Score up to Week 56 of Participants With >=3 Exacerbations in the Previous Year. | -4.264 (-5.136 to -3.391) | -2.391 (-3.260 to -1.523) |
The CAT is an 8-item PRO developed to measure the impact of COPD on health status. The instrument uses semantic differential 6-point response scales, which are defined by contrasting objectives to capture the impact of COPD. Content includes items related to cough, phlegm, chest tightness, breathlessness going up hills/stairs, activity limitation at home, confidence leaving home, sleep, and energy. The CAT total score is the sum of all item responses. Scores range from 0 to 40 with higher scores indicative of greater COPD impact on health status. A score cannot be calculated if \>2 responses are missing; when one or two items are missing, their scores can be set to the average of the non-missing item scores.
| Score | Benralizumab 100 mg | Placebo |
|---|---|---|
| Change From Baseline in COPD Assessment Tool (CAT) Total Score up to Week 56 of Participants With >=2 Exacerbations in the Previous Year. | -4.021 (-4.761 to -3.281) | -2.178 (-2.909 to -1.447) |
The E-RS: COPD is an 11-item PRO developed to evaluate the severity of respiratory symptoms of COPD. The E-RS: COPD is a subset of items from the EXACT-PRO. The E-RS: COPD was designed to be captured as part of the daily EXACT-PRO assessment. Summation of E-RS: COPD item responses produces a total score ranging from 0 to 40, with higher scores indicating greater severity. In addition to the total score, symptom domain scores can be calculated for breathlessness (5 items; score range: 0-17), cough and sputum (3 items; score range: 0-11) and chest symptoms (3 items; score range: 0-12) by summing the responses of items within a respective domain. As with the total score, higher domain scores indicate greater severity.
| Score | Benralizumab 100 mg | Placebo |
|---|---|---|
| Total Score | -2.32 ± 6.602 | -1.49 ± 5.343 |
| Breathlessness | -0.76 ± 3.409 | -0.41 ± 2.839 |
| Cough and Sputum | -0.77 ± 1.836 | -0.60 ± 1.593 |
| Chest Symptoms | -0.78 ± 2.224 | -0.48 ± 1.850 |
The E-RS: COPD is an 11-item PRO developed to evaluate the severity of respiratory symptoms of COPD. The E-RS: COPD is a subset of items from the EXACT-PRO. The E-RS: COPD was designed to be captured as part of the daily EXACT-PRO assessment. Summation of E-RS: COPD item responses produces a total score ranging from 0 to 40, with higher scores indicating greater severity. In addition to the total score, symptom domain scores can be calculated for breathlessness (5 items; score range: 0-17), cough and sputum (3 items; score range: 0-11) and chest symptoms (3 items; score range: 0-12) by summing the responses of items within a respective domain. As with the total score, higher domain scores indicate greater severity.
| Score | Benralizumab 100 mg | Placebo |
|---|---|---|
| Total Score | -1.95 ± 6.218 | -1.20 ± 5.245 |
| Breathlessness | -0.57 ± 3.196 | -0.29 ± 2.691 |
| Cough and Sputum | -0.67 ± 1.736 | -0.52 ± 1.576 |
| Chest Symptoms | -0.70 ± 2.071 | -0.39 ± 1.849 |
Respiratory related causes of death are summarised based on the SOC = Respiratory, thoracic and mediastinal disorders. Death per 100 participant-year is compared between treatment groups. Death per 100 participant-year is defined as number of subjects with death divided by the total number of days at risk for death across all subjects in given treatment group, multiplied by 365.25 and then multiplied by 100. Total number of days at risk for death is defined as the duration from the first dose of IP to the date of death, or the duration from the first dose of IP to last visit for subjects without death.
| Death per 100 participant-year | Benralizumab 100 mg | Placebo |
|---|---|---|
| All causes mortality | 3.00 | 5.05 |
| Respiratory-related mortality | 1.80 | 2.32 |
Respiratory related causes of death are summarised based on the SOC = Respiratory, thoracic and mediastinal disorders. Death per 100 participant-year is compared between treatment groups. Death per 100 participant-year is defined as number of subjects with a death divided by the total number of days at risk for death across all subjects in given treatment group, multiplied by 365.25 and then multiplied by 100. Total number of days at risk for death is defined as the duration from the first dose of IP to the date of death, or the duration from the first dose of IP to last visit for subjects without death.
| Death per 100 participant-year | Benralizumab 100 mg | Placebo |
|---|---|---|
| All causes mortality | 3.72 | 4.62 |
| Respiratory-related mortality | 2.13 | 2.31 |
Collected over AEs were collected from the first dose to the last date in study.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Benralizumab 100 mg | 28/331 (8.5%) | 155/331 (46.8%) | 175/331 (52.9%) |
| Placebo | 34/345 (9.9%) | 186/345 (53.9%) | 193/345 (55.9%) |
| Event | Benralizumab 100 mg | Placebo |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 87/331 | 103/345 |
| Infective exacerbation of chronic obstructive airways diseaseInfections and infestations | 29/331 | 21/345 |
| PneumoniaInfections and infestations | 23/331 | 21/345 |
| Pneumonia bacterialInfections and infestations | 3/331 | 9/345 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 4/331 | 8/345 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 7/331 | 2/345 |
| InfluenzaInfections and infestations | 7/331 | 6/345 |
| Covid-19Infections and infestations | 6/331 | 5/345 |
| Covid-19 pneumoniaInfections and infestations | 3/331 | 6/345 |
| Acute myocardial infarctionCardiac disorders | 5/331 | 4/345 |
| Event | Benralizumab 100 mg | Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 44/331 | 59/345 |
| Covid-19Infections and infestations | 48/331 | 47/345 |
| Upper respiratory tract infectionInfections and infestations | 31/331 | 43/345 |
| FallInjury, poisoning and procedural complications | 15/331 | 35/345 |
| Back painMusculoskeletal and connective tissue disorders | 26/331 | 20/345 |
| ConstipationGastrointestinal disorders | 26/331 | 16/345 |
| Urinary tract infectionInfections and infestations | 23/331 | 26/345 |
| PneumoniaInfections and infestations | 22/331 | 25/345 |
| HypertensionVascular disorders | 22/331 | 18/345 |
| HeadacheNervous system disorders | 20/331 | 20/345 |
All participants who were randomized and received any IP were included in the full analysis set.
| Age, Categorical(Participants) | Benralizumab 100 mg | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 122 | 136 | 258 |
| >=65 years | 209 | 209 | 418 |
| Age, Continuous(Years) | Benralizumab 100 mg | Placebo | Total |
|---|---|---|---|
| Mean | 67.0 ± 7.72 | 66.8 ± 7.28 | 66.9 ± 7.49 |
| Sex: Female, Male(Participants) | Benralizumab 100 mg | Placebo | Total |
|---|---|---|---|
| Female | 101 | 111 | 212 |
| Male | 230 | 234 | 464 |
| Ethnicity (NIH/OMB)(Participants) | Benralizumab 100 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 61 | 62 | 123 |
| Not Hispanic or Latino | 270 | 283 | 553 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Benralizumab 100 mg | Placebo | Total |
|---|---|---|---|
| White | 244 | 250 | 494 |
| Black or African American | 1 | 4 | 5 |
| Asian | 66 | 72 | 138 |
| Other | 20 | 19 | 39 |
Showing the first 100 of 342 sites across 30 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Aug 2019 to primary completion in Jul 2025, 71 months.
Results were first posted in Nov 2026, 1 year 3 months after primary completion.
Of 109 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 71 months is above that.
Counting every sponsor, half of 142 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab
Pulmonary Disease, Chronic Obstructive →